Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
30
First results from the phase III ALTTO trial (BIG 02-06; NCCTG 063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (TL) or their combination (L + T) in the adjuvant treatment of HER2-positive <br />early breast cancer (EBC) Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
description
First results from the phase III ALTTO trial (BIG 02-06; NCCTG 063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (TL) or their combination (L + T) in the adjuvant treatment of HER2-positive early breast cancer (EBC). - PowerPoint PPT Presentation
Transcript of Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
First results from the phase III ALTTO trial (BIG 02-06; NCCTG 063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (TL) or their combination (L + T) in the adjuvant treatment of HER2-positive <br />early breast cancer (EBC)
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
TARGETING HER2 IN BREAST CANCER: EVOLVING CONCEPTS
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
Slide 3
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
Slide 4
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
Slide 5
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
Slide 6
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
Slide 7
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
Primary Endpoint
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
SECONDARY EndpointS
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
STAtiStical considerations
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
Current Analysis Plan
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
Slide 12
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
CONSORT TABLE
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
Slide 14
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
Distribution of the Stratification Factors by Treatment Arm
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
Distribution of patient characteristics by Treatment Arm
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
Slide 17
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
DISEASE-FREE SURVIVAL (DFS) ANALYSIS
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
DFS BY Hormone Receptor Status
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
DFS by Chemotherapy Timing
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
OVERALL SURVIVAL (OS) ANALYSIS
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
DFS NON-INFERIORITY ANALYSIS<br />Note: Null hypothesis hazard ratio is 1.11
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
Slide 23
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
PROPORTION OF PATIENTS RECEIVING ≥ 85% OF THE PLANNED DOSE OF ANTI-HER2 DRUGS
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
Slide 25
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
MAIN DIFFERENCES IN AEs BY TREATMENT ARM
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
CARDIAC SAFETY
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
CONCLUSIONS (I)
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
CONCLUSIONS (II)
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
Acknowledgements
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
